DD from another poster: Rounded up some DD for
Post# of 72
(Total Views: 414)
Posted On: 09/08/2020 8:49:27 AM
DD from another poster:
Rounded up some DD for all the new incoming shareholders, great timing I might add since its been a extra month for the super 10k release which I think most anticipated. Even though the company leaders are very impressive and the accounting firm is huge and experienced, it was clear September would be the month. Don't want to be on the sidelines when that super 10 k hits.
Even at 1.00 this Biotech would only have a 14 million dollar market cap.
CRXM 14M OS Phase 3 , FAST TRACK FDA Drug Stock at a 1 million dollar market cap.
Marcum LLP serious accounting firm for serious players. Click on the link
https://www.marcumllp.com/offices
From 8K "Under the Preferred Stock Purchase Agreement, we have agreed to use our best efforts to become current in our reporting obligations under the Securities Exchange Act of 1934, as amended. We have engaged Marcum LLP as our independent public accounting firm to perform audits of our financial statements for the years ended December 31, 2017, 2018 and 2019. We intend to file a “super 10-K” report with the SEC covering each of those three fiscal years promptly following the completion of the audits, and thereafter to remain compliant with our public company reporting requirements."
https://www.otcmarkets.com/filing/html?id=141...WUD04P0tth
Those filings cost anywhere from 40 to 50 thousand dollars, the 8K stated those preferred shares that were sold for 1.7 million dollars, some of it will be used to pay for the accountants to audit and file with the SEC.
A privately held biotech, Nostrum Pharmaceuticals took position on this company, they funded the company through preferred shares 1.7 million dollars, which leads me to believe there could be a merger between the two companies which would just be a huge bonus.
Nostrum controls 91% of the CRXM
https://finance.yahoo.com/quote/CRXM/key-statistics/
CRXM - Forward looking events
1. SEC filing super 10K to bring finance current
2. Numerous press releases
3. Phase 3 clinical trial kickoff
Phase 3 of trials with the only competitor drug selling for $1.5b and CRXM is at a 1 million dollar market cap but thats about to drastically change in September.
I can't ever recall finding a 14M OS Phase 3 , FAST TRACK FDA Drug Stock at a 1 million dollar market cap.
Take a look at Angionetics website which is A Majority Owned Subsidiary of Gene Biotherapeutics Inc.
https://www.angionetics.com/
AFFIRM Phase 3 Trial info
https://clinicaltrials.gov/ct2/show/NCT029280...amp;rank=1
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : June 1, 2022
Talk about great timing to. Be on alert for the Super 10k from that very impressive accounting firm.
$CRXM
Rounded up some DD for all the new incoming shareholders, great timing I might add since its been a extra month for the super 10k release which I think most anticipated. Even though the company leaders are very impressive and the accounting firm is huge and experienced, it was clear September would be the month. Don't want to be on the sidelines when that super 10 k hits.
Even at 1.00 this Biotech would only have a 14 million dollar market cap.
CRXM 14M OS Phase 3 , FAST TRACK FDA Drug Stock at a 1 million dollar market cap.
Marcum LLP serious accounting firm for serious players. Click on the link
https://www.marcumllp.com/offices
From 8K "Under the Preferred Stock Purchase Agreement, we have agreed to use our best efforts to become current in our reporting obligations under the Securities Exchange Act of 1934, as amended. We have engaged Marcum LLP as our independent public accounting firm to perform audits of our financial statements for the years ended December 31, 2017, 2018 and 2019. We intend to file a “super 10-K” report with the SEC covering each of those three fiscal years promptly following the completion of the audits, and thereafter to remain compliant with our public company reporting requirements."
https://www.otcmarkets.com/filing/html?id=141...WUD04P0tth
Those filings cost anywhere from 40 to 50 thousand dollars, the 8K stated those preferred shares that were sold for 1.7 million dollars, some of it will be used to pay for the accountants to audit and file with the SEC.
A privately held biotech, Nostrum Pharmaceuticals took position on this company, they funded the company through preferred shares 1.7 million dollars, which leads me to believe there could be a merger between the two companies which would just be a huge bonus.
Nostrum controls 91% of the CRXM
https://finance.yahoo.com/quote/CRXM/key-statistics/
CRXM - Forward looking events
1. SEC filing super 10K to bring finance current
2. Numerous press releases
3. Phase 3 clinical trial kickoff
Phase 3 of trials with the only competitor drug selling for $1.5b and CRXM is at a 1 million dollar market cap but thats about to drastically change in September.
I can't ever recall finding a 14M OS Phase 3 , FAST TRACK FDA Drug Stock at a 1 million dollar market cap.
Take a look at Angionetics website which is A Majority Owned Subsidiary of Gene Biotherapeutics Inc.
https://www.angionetics.com/
AFFIRM Phase 3 Trial info
https://clinicaltrials.gov/ct2/show/NCT029280...amp;rank=1
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Estimated Study Start Date : January 1, 2020
Estimated Primary Completion Date : January 1, 2022
Estimated Study Completion Date : June 1, 2022
Talk about great timing to. Be on alert for the Super 10k from that very impressive accounting firm.
$CRXM
(0)
(0)